Caldan Therapeutics

About:

Caldan Therapeutics Ltd, a spin-out from a long-standing collaboration between Professor Trond Ulven at the University of Southern Denmark

Website: http://www.caldantherapeutics.com

Twitter/X: caldanthera

Top Investors: Eli Lilly, LifeArc, Scottish Enterprise, Epidarex Capital, Pitch@Palace

Description:

Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications. The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU). Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.